- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Wendy Niebler, Shire
S
Wendy Niebler
Vice President, Global Medical Affairs, ADHD, Shire
EDUCATION: DO from Ohio University College ofOsteopathic Medicine, MBA from St. Joseph's University
ACCOMPLISHMENT: Designed Cephalon's largest global clinical program in under two years
On joining the pharma industry:
I started out as a physician in private practice. But the scientific aspect of clinical trial work motivated me to join Cephalon, because I had a chance to not only run, but design, clinical trials. It was an opportunity of a lifetime. As a physician going to industry, you can miss that day-to-day contact with patients. But it's reassuring to know you can impact patients even in a wider sense.
Wendy Niebler
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
